Kohjin Bio Co

Kohjin Bio Co ROE

The Return on Equity (ROE) of Kohjin Bio Co (177A.T) as of Nov 3, 2026 is 13.75 %. In the previous year, Return on Equity (ROE) was 11.52 % — a change of 19.34% (higher).

ROE

13.75 %

YoY

19.34%

Last updated:

In 2025, Kohjin Bio Co's return on equity (ROE) was 13.75 %, a 19.34% increase from the 11.52 % ROE in the previous year.

The Kohjin Bio Co ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2022
26.51 JPY
Jan 1, 2023
27.50 JPY
Jan 1, 2024
11.52 JPY
Jan 1, 2025
13.75 JPY
The Kohjin Bio Co ROE history
YEARROEYoY
13.75 %+19.34%
11.52 %-58.11%
27.50 %+3.72%
26.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kohjin Bio Co Stock analysis

What does Kohjin Bio Co do? Kohjin Bio Co Ltd generates revenue through three business segments. The Tissue Culture segment sells serum-free media for regenerative medicine and immunotherapy research, targeting research institutions and biotech companies. The Microbiology segment offers pathogen testing media for clinical, food, and pharmaceutical quality control, purchased by hospitals, food producers, and cosmetics manufacturers. The Cell Processing segment provides contract cell processing services to medical institutions under the Regenerative Medicine Safety Act, with facilities approved for manufacturing specified cell products. Revenue comes from direct sales of media products and service contracts for cell processing operations. The company's products include bacterial testing media, in vitro diagnostic drugs, and cell culture media, all sold under its own brand. Medical institutions, research organizations, and quality control departments in food and pharmaceutical industries are the primary buyers. The Microbiology segment serves clinical laboratories and food safety testing facilities, while the Tissue Culture segment caters to regenerative medicine research centers. Cell Processing services are contracted by hospitals and clinics requiring specialized cell manufacturing under regulatory compliance. Kohjin Bio's business model relies on selling specialized media for laboratory and medical applications, with recurring revenue from long-term contracts in cell processing. The Microbiology segment's products are used in routine pathogen testing, ensuring steady demand from healthcare and food sectors. The Tissue Culture segment's serum-free media support emerging therapies, attracting biotech firms seeking advanced research tools. Cell Processing services are driven by Japan's expanding regenerative medicine market, where medical institutions outsource cell manufacturing to compliant facilities. Kohjin Bio Co is one of the most popular companies on Eulerpool.

ROE Details

Decoding Kohjin Bio Co's Return on Equity (ROE)

Kohjin Bio Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Kohjin Bio Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Kohjin Bio Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Kohjin Bio Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Kohjin Bio Co stock

Return on Equity (ROE) of Kohjin Bio Co is 13.75 % in 2025.

Return on Equity (ROE) of Kohjin Bio Co changed from 11.52 % to 13.75 %, representing a 19.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Kohjin Bio Co since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Kohjin Bio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Kohjin Bio Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Kohjin Bio Co